Page 32 of 448: studies 311 to 320 of 4,475, newest first. Back to the ketamine overview
May 27, 2026 James Phelps
A new randomized trial found serial intravenous ketamine was not significantly more effective than the active placebo midazolam in reducing depressive symptoms or improving quality of life. While the study may have been underpowered due to a small sample size (n=63), the improvement in MADRS scores fell short of the minimal clinically important difference. The study faced blinding failures,...
Research Square May 27, 2026 Tychique T. Wasolua, Tanner J. Bommersbach, Roger S McIntyre et al. preprint
Abstract Ketamine and esketamine are increasingly used as rapid-acting antidepressants, yet concerns remain regarding potential structural neurotoxicity, particularly with chronic or high-dose exposure. Despite expanding clinical use, no comprehensive systematic review has integrated neurotoxicity evidence across preclinical and human studies while formally evaluating methodological quality....
Expert Opinion on Investigational Drugs May 26, 2026 Mina Takahashi, Richard C. Shelton
INTRODUCTION: Bipolar depression with acute suicidal ideation and behavior (ASIB) is a life- threatening manifestation of bipolar disorder (BD), with a suicide risk higher than that in other psychiatric disorders and the general population. Rapid and effective interventions are critical, as traditional therapies are often slow and frequently insufficient. Currently, no drug is approved by the...
Mental Health Weekly May 25, 2026 Valerie A. Canady
New findings published this month in The American Journal of Psychiatry (AJP) on the use of ketamine followed by ultra‐low‐dose buprenorphine to sustain reductions in suicidal ideation are drawing attention from suicide prevention experts, who say the approach may help address a long‐standing gap in treatment during high‐risk periods following a crisis (see related story, p. 3).
Pharmacology, Biochemistry, and Behavior May 25, 2026 Marcela Unterspann, Chrysostomos Charalambous, Martin Votava et al.
Anxiety- and stress-related disorders are commonly treated using combinations of centrally acting drugs. However, the behavioral outcomes of interactions between GABAergic and glutamatergic systems remain incompletely characterized. The present study investigated the effects of flumazenil, ketamine and midazolam, and their combinations, on anxiety-like behavior in adult male rats using aversive...
Dijlah Journal of Medical Sciences P-ISSN 3078-3178 E-ISSN 3078-8625 May 23, 2026 Suha Adel Qasim Al-Ani
Postoperative hallucinations and other psychotropic effects are known side effects, which may be dose-dependent. Higher doses exacerbate these changes, prolonging dissociative and hallucinatory experiences postoperatively. The study aimed to evaluate the effect of ketamine different doses on postoperative hallucination (score and types). This study was applied on (62) persons including (32)...
Psychiatry Research Case Reports May 22, 2026 Albert Yeung, Huiqiong Deng, Wendy Feng et al.
Background Posttraumatic stress disorder (PTSD) remains a challenging condition to treat. Nonpsychedelic pharmacotherapies have modest efficacy, and trauma-focused therapies such as Cognitive Behavioral Therapy (CBT) and Eye Movement Desensitization and Reprocessing (EMDR) demonstrate higher response rates than medications, yet they suffer from high dropout rates (25–35%) and limited...
Psychopharmacology May 22, 2026 Wei-Chen Lin, Li-Kai Cheng, Tung-Ping Su et al.
Background: Studies have demonstrated that subanesthetic-dose ketamine may modulate the functioning of specific depression-related brain regions, particularly the anterior cingulate cortex and prefrontal cortex. However, how subanesthetic-dose ketamine alters the global and regional graph theory metrics of resting-state functional connectivity in patients with treatment-resistant depression...
Therapeutic Advances in Psychopharmacology May 22, 2026 Liliana Patarroyo-Rodriguez, Vanessa K. Pazdernik, Jennifer L. Vande Voort et al.
Background: Ketamine and esketamine ((es)ketamine) rapidly reduce depressive symptoms and suicidal ideation (SI) in treatment-resistant depression (TRD), but whether early SI improvement during the acute phase of the treatment predicts reduced suicide-associated emergency department (SAED) visits over the longer term remains unclear. Objectives: To examine whether early improvements in SI,...
Alcoholism & Drug Abuse Weekly May 21, 2026 Alison Knopf
New research on the relationship between cannabis and psychosis was released, and a presentation on how low‐dose buprenorphine combined with ketamine reduced suicidality in adults with major depressive disorder was published and presented at the annual meeting of the American Psychiatric Association (APA).